文献速递血液净化与透析

倾向性评分匹配比较腹膜透析与中心血液透析死亡率的系统综述与Meta分析

Propensity score matched mortality comparisons of peritoneal and in-centre haemodialysis: systematic review and meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该系统综述与Meta分析纳入17项队列研究、共113 578例倾向性评分匹配的新发透析患者,比较腹膜透析与中心血液透析的死亡风险。汇总风险比(HR)为1.06(95%CI 0.99-1.14),提示两种透析方式生存获益相当。异质性较大,主要由队列时期、研究类型和国家来源解释。

要点

  • 腹膜透析与中心血液透析的汇总死亡风险无显著差异,HR 1.06(95%CI 0.99-1.14)。
  • 按地区分层后死亡风险基本不变,欧洲、亚洲、美洲HR分别为1.04、1.14、0.98。
  • 糖尿病与非糖尿病患者亚组风险相似,HR分别为1.09和0.99。

核心结论

  • 腹膜透析与中心血液透析的生存获益相当,HR 1.06(95%CI 0.99-1.14)。

研究设计与样本

  • 系统综述与随机效应Meta分析,纳入17项倾向性评分匹配的队列研究,共113 578例新发透析患者,队列期1993-2014年。

主要发现

  • 腹膜透析vs中心血液透析的汇总HR为1.06(95%CI 0.99-1.14)。
  • 欧洲、亚洲、美洲队列的HR分别为1.04(95%CI 0.94-1.15)、1.14(95%CI 0.99-1.32)、0.98(95%CI 0.87-1.10)。
  • 糖尿病亚组HR为1.09(95%CI 0.98-1.21),非糖尿病亚组HR为0.99(95%CI 0.90-1.09)。
  • 异质性I2=87%,队列时期、研究类型和国家来源共同解释90.6%的组间方差(R2=90.6%)。

临床怎么用

  • 在向患者咨询透析方式选择时,可告知腹膜透析与中心血液透析的生存获益总体相当。

局限性

  • 异质性较大(I2=87%),结果受队列时期、研究类型和国家来源等因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate comparisons of haemodialysis (HD) and peritoneal dialysis (PD) survival based on observational studies are difficult due to substantial residual confounding that arises from imbalances between treatments. Propensity score matching (PSM) comparisons confer additional advantages over conventional methods of adjustment by further reducing selection bias between treatments. We conducted a systematic review of studies that compared mortality between in-centre HD with PD using a PSM-based approach. METHODS: A sensitive search strategy identified all citations in the PubMed, Cochrane and EMBASE databases from inception through November 2018. Pooled PD versus HD mortality hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated through random-effects meta-analysis. A subsequent meta-regression explored factors to account for between-study variation. RESULTS: The systematic review yielded 214 citations with 17 cohort studies and 113 578 PSM incident dialysis patients. Cohort periods spanned the period 1993-2014. The pooled HR for PD versus HD was 1.06 (95% CI 0.99-1.14). There was considerable variation by country, however, mortality risks for PD versus HD remained virtually unchanged when stratified by geographical region with HRs of 1.04 (95% CI 0.94-1.15), 1.14 (95% CI 0.99-1.32) and 0.98 (0.87-1.10) for European, Asian and American cohorts, respectively. Subgroup meta-analyses revealed similar risks for patients with diabetes [HR 1.09 (95% CI 0.98-1.21)] and without diabetes [HR 0.99 (95% CI 0.90-1.09)]. Heterogeneity was substantial (I2 = 87%) and was largely accounted for by differences in cohort period, study type and country of origin. Together these factors explained a substantial degree of between-studies variance (R2 = 90.6%). CONCLUSIONS: This meta-analysis suggests that PD and in-centre HD carry equivalent survival benefits. Reported differences in survival between treatments largely reflect a combination of factors that are unrelated to clinical efficacy.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Elsayed ME, Morris AD, Li X, et al. Propensity score matched mortality comparisons of peritoneal and in-centre haemodialysis: systematic review and meta-analysis. Nephrol Dial Transplant. 2020. PMID: 31981353. doi:10.1093/ndt/gfz278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。